You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

412 Results
Document
Jul 2022
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Updated
Jun 2025
Document
Nov 2022
Document
Nov 2022
Document
Jan 2023
Document
Jan 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
fluorouracil,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Drug
Other Name(s): Inrebic®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Guidelines and Advice
Status: Current
Version: 2
Updated
Sep 2025
Document
Apr 2023
Document
Apr 2023
.

Pages